<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Failure</title>
	<atom:link href="http://www.tapanray.in/tag/failure/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Impact of The Cost of Pharma Marketing Failure On Patients</title>
		<link>http://www.tapanray.in/impact-of-the-cost-of-pharma-marketing-failure-on-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=impact-of-the-cost-of-pharma-marketing-failure-on-patients</link>
		<comments>http://www.tapanray.in/impact-of-the-cost-of-pharma-marketing-failure-on-patients/#comments</comments>
		<pubDate>Mon, 12 Sep 2022 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[area]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[controllable]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[send]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[uncontrollable]]></category>
		<category><![CDATA[variables]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10707</guid>
		<description><![CDATA[‘About half of all products launched over the past 15 years have underperformed pre-launch consensus forecasts by more than 20%.’ It’s one of the findings of a recent study by L.E.K. Consulting, going back to 2004. This number is besides the cost of &#8230; <a href="http://www.tapanray.in/impact-of-the-cost-of-pharma-marketing-failure-on-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/impact-of-the-cost-of-pharma-marketing-failure-on-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Pays More: Creating ‘Innovative ‘Customer Experience’ Or ‘Innovative Drugs’?</title>
		<link>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-pays-more-creating-innovative-customer-experience-or-innovative-drugs</link>
		<comments>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/#comments</comments>
		<pubDate>Mon, 13 Jan 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[business corporate]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Consumerism]]></category>
		<category><![CDATA[Creating]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[dimension]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[equation]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[life-cycle]]></category>
		<category><![CDATA[loyal]]></category>
		<category><![CDATA[loyalty]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pays]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[prodrugs]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[word-of-mouth]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9851</guid>
		<description><![CDATA[More innovative a drug is, the better is its business success rate. This was the general perception of around 92 percent pharma professionals in the past three years. Whereas the fact is: ‘Having the best product doesn’t guarantee sales anymore’. &#8230; <a href="http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dawns A New Era: Regenerative Medicine For Degenerative Disease</title>
		<link>http://www.tapanray.in/dawns-a-new-era-regenerative-medicine-for-degenerative-disease/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dawns-a-new-era-regenerative-medicine-for-degenerative-disease</link>
		<comments>http://www.tapanray.in/dawns-a-new-era-regenerative-medicine-for-degenerative-disease/#comments</comments>
		<pubDate>Mon, 17 Jul 2017 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cells]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[cure]]></category>
		<category><![CDATA[degeneration]]></category>
		<category><![CDATA[degenerative]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[health care]]></category>
		<category><![CDATA[Heart]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ischemia]]></category>
		<category><![CDATA[Macular]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[multiple]]></category>
		<category><![CDATA[Parkinson's]]></category>
		<category><![CDATA[patch]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regenerative]]></category>
		<category><![CDATA[sclerosis]]></category>
		<category><![CDATA[stem]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8321</guid>
		<description><![CDATA[Could breakthrough innovation in ‘Regenerative Medicine’ significantly reduce the need of expensive lifelong medications, or even make the use of some important medical devices less relevant, or even help avoiding expensive and risky surgical interventions? The common answer to these &#8230; <a href="http://www.tapanray.in/dawns-a-new-era-regenerative-medicine-for-degenerative-disease/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dawns-a-new-era-regenerative-medicine-for-degenerative-disease/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Price Control in India: When A Local Media Goes Against, A Global CEO Doesn’t</title>
		<link>http://www.tapanray.in/drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt</link>
		<comments>http://www.tapanray.in/drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt/#comments</comments>
		<pubDate>Sun, 13 Nov 2016 23:40:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[AIDAN]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[cheapest]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[demonetization]]></category>
		<category><![CDATA[Donald]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Economic Times]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Estate]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Forty]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[gratification]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7963</guid>
		<description><![CDATA[‘Variety is the spice of life’, as the good old saying goes. The week, just gone by, was indeed packed with a wide variety of surprises, well encompassing various important areas, some of which are as follows: Effective November 08, &#8230; <a href="http://www.tapanray.in/drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-price-control-in-india-when-a-local-media-goes-against-a-global-ceo-doesnt/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘The Memory Thief’ Still Eludes Grasp Of Pharma R&amp;D</title>
		<link>http://www.tapanray.in/the-memory-thief-still-eludes-grasp-of-pharma-rd/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-memory-thief-still-eludes-grasp-of-pharma-rd</link>
		<comments>http://www.tapanray.in/the-memory-thief-still-eludes-grasp-of-pharma-rd/#comments</comments>
		<pubDate>Mon, 01 Feb 2016 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ADEAR]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[brain]]></category>
		<category><![CDATA[bullet]]></category>
		<category><![CDATA[center]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[eludes]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[flickers]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[grasp]]></category>
		<category><![CDATA[Hope]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inflammation]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[Mayo]]></category>
		<category><![CDATA[Memory]]></category>
		<category><![CDATA[microglia]]></category>
		<category><![CDATA[MNT]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[plaque]]></category>
		<category><![CDATA[prevalence]]></category>
		<category><![CDATA[progression]]></category>
		<category><![CDATA[prowl]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Southhampton]]></category>
		<category><![CDATA[tangles]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tau]]></category>
		<category><![CDATA[thief]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[UCLA]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[‘The Memory Thief’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7420</guid>
		<description><![CDATA[Over several decades, in fact, since its very inception, pharma R&#38;D has been playing a crucial role in alleviating diseases of various types &#8211; from severe acute infections, to a large variety of non-infectious chronic illnesses, including many dreaded diseases, &#8230; <a href="http://www.tapanray.in/the-memory-thief-still-eludes-grasp-of-pharma-rd/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-memory-thief-still-eludes-grasp-of-pharma-rd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Universal Health Coverage: The Only Alternative To Drug Price Control in India?</title>
		<link>http://www.tapanray.in/universal-health-coverage-the-only-alternative-to-drug-price-control-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=universal-health-coverage-the-only-alternative-to-drug-price-control-in-india</link>
		<comments>http://www.tapanray.in/universal-health-coverage-the-only-alternative-to-drug-price-control-in-india/#comments</comments>
		<pubDate>Mon, 09 Nov 2015 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Boston]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[foolhardy]]></category>
		<category><![CDATA[Globe]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NHP]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Right to Health]]></category>
		<category><![CDATA[Supreme Court]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Turing]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[‘Committee on Oversight & Government Reform’]]></category>
		<category><![CDATA[‘Kaiser Health Tracking Poll’]]></category>
		<category><![CDATA[“National Health Assurance”]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7257</guid>
		<description><![CDATA[Aggressive drug pricing is becoming a burning issue in the healthcare space, across the world. The raging debate continues in India too, fueled by many factors. In this context, it was quite interesting to note, on July 15, 2015, the &#8230; <a href="http://www.tapanray.in/universal-health-coverage-the-only-alternative-to-drug-price-control-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/universal-health-coverage-the-only-alternative-to-drug-price-control-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Price Control in India: A Fresh Advocacy With Blunt Edges</title>
		<link>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges</link>
		<comments>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/#comments</comments>
		<pubDate>Mon, 07 Sep 2015 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[Authority]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[blunt]]></category>
		<category><![CDATA[campaign]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[cheapest]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[cutting]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[edges]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[income]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Para 19]]></category>
		<category><![CDATA[parity]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pharmasofttech]]></category>
		<category><![CDATA[power]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[purchasing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Yeh dil maange more]]></category>
		<category><![CDATA[“Assessing the Impact of Price Control Measures on Access to Medicines in India”]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7017</guid>
		<description><![CDATA[It is no-brainer that the advocacy initiatives to influence the new Government doing away with the ‘Drug Price Control’ in India has re-started by flooring the gas pedal. A fresh invigorating effort, apparently a pretty expensive one, has been initiated &#8230; <a href="http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s Drug Pricing Policy: “Absurd, Unreasonable And Irrational&#8221; – Supreme Court</title>
		<link>http://www.tapanray.in/indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court</link>
		<comments>http://www.tapanray.in/indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court/#comments</comments>
		<pubDate>Mon, 20 Jul 2015 00:00:36 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1996]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Achhe din]]></category>
		<category><![CDATA[All India Drug Action Network]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[coat-based drug pricing]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[irrational]]></category>
		<category><![CDATA[JSA]]></category>
		<category><![CDATA[lawmakers]]></category>
		<category><![CDATA[Market Based Drug-Pricing]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy. Absurd]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Supreme Court]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Unreasonable]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6830</guid>
		<description><![CDATA[On July 15, 2015, while hearing a petition related to the current &#8216;Market Based Drug-Pricing Policy&#8217; of the country, the Supreme Court of India expressed its bewilderment on the very rationality of the ‘National Pharmaceutical Pricing Policy 2012’ and directed the &#8230; <a href="http://www.tapanray.in/indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does ‘Free-Market Economy’ Work For Branded Generic Drugs In India?</title>
		<link>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-free-market-economy-work-for-branded-generic-drugs-in-india</link>
		<comments>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/#comments</comments>
		<pubDate>Mon, 27 Apr 2015 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Badm Medicine]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[chemicals. and. fertilizers]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[Delhi School of Economics]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DoP. department of pharmaceuticals]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DSE]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[Free Market Economy]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[IJME]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[paradox]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[‘Dorfman-Steiner’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6557</guid>
		<description><![CDATA[On April 20, 2015, a panel of 31 lawmakers of the Standing Committee on Chemicals and Fertilizers tabled its report in the Indian Parliament. The committee emphasized that patients in India should have access to all medicines, including life saving drugs, &#8230; <a href="http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
